⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4486696 | 0.88 | TSHR (0.36) | — | |
| SCHEMBL12215973 | 0.75 | TSHR (0.36) | — | |
| SCHEMBL12215971 | 0.73 | TSHR (0.31) | — | |
| SCHEMBL4267200 | 0.73 | TSHR (0.35) | — | |
| SCHEMBL12215976 | 0.73 | GAA (0.40) | — | |
| SCHEMBL2031804 | 0.67 | HDAC4 (0.46) | — | |
| SCHEMBL31041077 | 0.67 | HDAC4 (0.46) | — | |
| SCHEMBL16539249 | 0.67 | NOS2 (0.41) | — | |
| SCHEMBL6268220 | 0.67 | MAOB (0.50) | — | |
| SCHEMBL11292416 | 0.67 | NOS1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025095666-A1 | NOVEL OXOCYANINE-BASED COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 포항공과대학교 산학협력단 | 2025-05-08 | — | — | WO | claimed |
| US-20100226938-A1 | Cellular and viral inactivation | HEALTH AND HUMAN SERVICES, GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF | 2010-09-09 | — | — | US | claimed |
| US-20090297558-A1 | Inactivated Influenza Virus Compositions | DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH, GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE | 2009-12-03 | — | — | US | claimed |
| WO-2008054481-A2 | IMPROVED INACTIVATED INFLUENZA VIRUS COMPOSITIONS | GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH (US) | 2008-05-08 | — | — | WO | claimed |
| CN-1954066-A | Cellular and viral inactivation | US GOVERNMENT (US) | 2007-04-25 | — | — | CN | claimed |
| EP-1727894-A1 | CELLULAR AND VIRAL INACTIVATION | Government of the United States of America as represented by The Secretary of the Department of Health and Human Services (US) | 2006-12-06 | — | — | EP | claimed |
| WO-2005093049-A1 | CELLULAR AND VIRAL INACTIVATION | GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-10-06 | — | — | WO | claimed |
| US-12297461-B2 | Methods of producing and characterizing virus vaccine and virus vaccine composition | GUANGZHOU REALBENEFITSPOT PHARMACEUTICAL CO., LTD. (CN) | 2025-05-13 | — | — | US | disclosed |
| WO-2025095666-A1 | NOVEL OXOCYANINE-BASED COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 포항공과대학교 산학협력단 | 2025-05-08 | — | — | WO | disclosed |
| EP-4382183-A2 | METHODS OF PRODUCING AND CHARACTERIZING VIRUS VACCINE AND VIRUS VACCINE COMPOSITION | Guangzhou Realbenefitspot Pharmaceutical Co., Ltd. (CN) | 2024-06-12 | — | — | EP | disclosed |
| EP-3420076-B1 | METHODS OF PRODUCING AND CHARACTERIZING VIRUS VACCINE AND VIRUS VACCINE COMPOSITION | GUANGZHOU REALBENEFITSPOT PHARMACEUTICAL CO LTD (CN) | 2024-02-21 | — | — | EP | disclosed |
| US-20220333085-A1 | METHODS OF PRODUCING AND CHARACTERIZING VIRUS VACCINE AND VIRUS VACCINE COMPOSITION | GUANGZHOU REALBENEFITSPOT PHARMACEUTICAL CO., LTD. (CN) | 2022-10-20 | — | — | US | disclosed |
| US-11319529-B2 | Methods of producing and characterizing virus vaccine and virus vaccine composition | GUANGZHOU REALBENEFITSPOT PHARMACEUTICAL CO., LTD. (CN) | 2022-05-03 | — | — | US | disclosed |
| US-20110038890-A1 | Cellular And Viral Inactivation | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2011-02-17 | — | — | US | disclosed |
| WO-2010116096-A1 | METHOD FOR PURIFYING THE RABIES VIRUS | SANOFI PASTEUR (FR) | 2010-10-14 | — | — | WO | disclosed |
| US-20100260798-A1 | Method for purifying the rabies virus | SANOFI PASTEUR (FR) | 2010-10-14 | — | — | US | disclosed |
| US-20100226938-A1 | Cellular and viral inactivation | HEALTH AND HUMAN SERVICES, GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF | 2010-09-09 | — | — | US | disclosed |
| US-20090297558-A1 | Inactivated Influenza Virus Compositions | DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH, GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE | 2009-12-03 | — | — | US | disclosed |
| US-20090297558-A1 | Inactivated Influenza Virus Compositions | DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH, GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE | 2009-12-03 | — | — | US | disclosed |
| WO-2008054481-A2 | IMPROVED INACTIVATED INFLUENZA VIRUS COMPOSITIONS | GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH (US) | 2008-05-08 | — | — | WO | disclosed |